FDA Approves SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — ORIG Submission by RUBICON RESEARCH, Not disclosed in the FDA record.

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows RUBICON RESEARCH as the sponsor of SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, with the generic name recorded as unspecified and dosage form TABLET. An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards. This specific application is submission type ORIG (submission number 1) under application number ANDA220884, with a submission status date of 20260910. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

RUBICON RESEARCH’s FDA history

Argus HQ has recorded 3 total FDA actions tied to RUBICON RESEARCH: 0 warning letters, 0 recalls, 3 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

What does the submission type mean?

An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards.

Is this product available now?

FDA's record lists a submission status date of 20260910. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Does RUBICON RESEARCH have other FDA approval records?

Yes. Argus HQ has recorded 3 total FDA actions tied to RUBICON RESEARCH, including 3 approval records.

What is the FDA application number for this submission?

FDA application number ANDA220884, submission 1.

Related enforcement actions

• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: ISOTRETINOIN (unspecified) →
• Approval (recent): BAYER HEALTHCARE — NDA approval: HYRNUO (unspecified) →
• Approval (recent): HETERO LABS LTD V — ANDA approval: IBRUTINIB (unspecified) →
• Approval (recent): MICRO LABS — ANDA approval: TOPIRAMATE (unspecified) →
• Approval (recent): LUPIN — ANDA approval: MODAFINIL (unspecified) →
• Approval (recent): ASTRAZENECA PHARMACEUTICALS, LP — NDA approval: ETCAMAH (unspecified) →
• Approval (recent): BPI LABS — ANDA approval: TESTOSTERONE CYPIONATE (unspecified) →
• Approval (recent): ZHEJIANG JUTAI PHARM — ANDA approval: BRIVARACETAM (unspecified) →